Improving cancer screening in the EU

Improving cancer screening in the EU

SAPEA report

24. June, 2022/by Hana Gasper

Disclaimer
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

This web page is not intended for reporting adverse drug reactions and other safety information.

Slovenia
Please report the suspected adverse reactions that you notice during drug therapy in accordance with the Rules on the Pharmacovigilance of medicinal products for human use (Official Gazette of the Republic of Slovenia, No. 57/14 and 27/17), in the way it is published on the website www.jazmp.si.

Roche contacts for collecting safety information regarding Roche medicinal products: slovenia.drugsafety@roche.com.

Croatia
Please report the suspected adverse reactions that you notice during drug therapy in accordance with the Ordinance on Monitoring Adverse Incidents Related to Medical Devices (Official Gazette, no. 125/13) in the way it is published on the website http://www.halmed.hr/

Roche contacts for collecting safety information regarding Roche medicinal products: croatia.info.ci1@roche.com.

Bosnia and Herzegovina
Please report the suspected adverse reactions that you notice during drug therapy in accordance with the Ordinance On Advertising Of Medicinal Products And Medical Devices (Official Gazette, no. 58/12) in the way it is published on the website http://www.almbih.gov.ba/

Roche contacts for collecting safety information regarding Roche medicinal products: bosnia.drugsafety@roche.com.

You might also like

Contact

Slovenia

Croatia